Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib

    Naoki Yamamoto, Takahiro Yamasaki, Taro Takami … Isao Sakaida
    Studysummary In this study, combining deferasirox with sorafenib significantly reduced liver fibrosis and preneoplastic lesions in rats while also lessening adverse effects compared to sorafenib alone.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jstage.jst.go.jp →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Pathogenesis of Hand-Foot Syndrome Induced by PEG-Modified Liposomal Doxorubicin Human cell · 2013